Retatrutide and Hepatic Fat Oxidation

Non-alcoholic fatty liver disease (NAFLD) affects over 100 million Americans and is rapidly becoming the leading cause of liver transplantation. The liver, designed to process and distribute dietary fat, becomes overwhelmed by excess caloric intake and insulin resistance, accumulating fat deposits that drive inflammation, scarring (fibrosis), and eventually cirrhosis. Retatrutide may be the most powerful pharmaceutical tool ever developed against this condition, thanks to its glucagon receptor's direct effect on hepatic fat oxidation (Jastreboff et al., NEJM 2023).

How Glucagon Drives Hepatic Fat Oxidation

The glucagon receptor is expressed abundantly on hepatocytes (liver cells). When activated by retatrutide, it triggers a cascade of metabolic changes that fundamentally shift the liver from fat storage to fat burning:

Phase 2 Liver Fat Results

The Phase 2 retatrutide trial included liver fat assessments using MRI-based proton density fat fraction (PDFF), the gold standard for non-invasive liver fat measurement. The results were remarkable:

• Liver fat reduction: Some participants showed liver fat reductions exceeding 80% from baseline
• Normalization: Many participants achieved normal liver fat levels (below 5% PDFF) by the end of the treatment period
• Dose response: Higher retatrutide doses produced greater liver fat reduction, consistent with a glucagon-receptor-mediated mechanism
• Speed: Significant reductions were observed within the first 24 weeks of treatment

These results are substantially greater than what semaglutide or tirzepatide produce for liver fat reduction, despite those medications also producing meaningful improvements through weight loss alone. The difference is attributable to retatrutide's direct glucagon-driven hepatic fat oxidation.

Implications for Fatty Liver Disease

Fatty liver disease progresses through stages: simple steatosis (fat accumulation), steatohepatitis (inflammation), fibrosis (scarring), and cirrhosis (irreversible damage). The earlier stages are reversible if the underlying cause (excess liver fat) is addressed.

Retatrutide's ability to dramatically reduce liver fat could potentially:

• Reverse simple steatosis: By reducing liver fat below the 5% diagnostic threshold, potentially achieving histologic resolution of early-stage NAFLD (an investigational endpoint, not an FDA-approved indication)
• Halt inflammation: Reducing the fat that triggers hepatocyte damage and inflammatory cascades
• Prevent fibrosis progression: By addressing the root cause before irreversible scarring occurs
• Improve liver function tests: ALT and AST normalization as liver cell damage decreases

Beyond the Liver: Systemic Fat Oxidation

Glucagon's fat oxidation effects are not limited to the liver. Peripheral tissues also experience increased fat mobilization and oxidation, though the liver is the primary target due to its high glucagon receptor density. The systemic increase in fat oxidation contributes to total energy expenditure and helps explain why retatrutide preferentially targets fat mass during weight loss (75-80% of weight lost is fat, compared to 60-65% with semaglutide).

The TRIUMPH-3 MASH Trial

Eli Lilly is conducting TRIUMPH-3, a Phase 3 trial specifically evaluating retatrutide for MASH (previously called NASH). This trial will assess:

• Resolution of steatohepatitis without worsening of fibrosis
• Improvement in liver fibrosis stage
• Liver fat reduction as measured by MRI-PDFF
• Long-term hepatic safety

If successful, retatrutide could become the first triple-agonist treatment approved for both obesity and liver disease, addressing two conditions that frequently coexist.

To explore currently available weight loss treatments, visit our treatments page.